On February 4, 2021, Tanaka, Yuta; Tanaka, Yuta; Kikuchi, Fumiaki; Yamamoto, Takeshi; Nakamura, Minoru; Takami, Kazuaki; Murakami, Masataka; Daini, Masaki; Wada, Yasufumi; Kakegawa, Keiko; Kasahara, Takahito; Ohashi, Tomohiro; Wang, Junsi; Ikeda, Zenichi; Puenner, Florian; Seto, Masaki; Mikami, Satoshi; Sasaki, Minoru published a patent.Related Products of 50743-01-6 The title of the patent was Heterocyclic compound for Gaucher disease. And the patent contained the following:
Provided is a compound which has a glucosylceramide synthase-inhibiting activity and is expected to be useful as a prophylactic or therapeutic agent for a lysosomal storage disease (e.g., Gaucher disease, Fabry disease, GM1-gangliosidosis, GM2 activation factor deficiency disease, Tay-Sachs disease, Sandhoff disease), a neurodegenerative disease (e.g., Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy) and the like. The present invention relates to a compound represented by formula (I); or a salt thereof. The experimental process involved the reaction of 5-Bromo-1H-imidazole-4-carbaldehyde(cas: 50743-01-6).Related Products of 50743-01-6
The Article related to glucosylceramide synthase heterocyclic compound gaucher disease, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 50743-01-6
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem